We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genzyme has resolved the shortage of its Gaucher’s disease treatment Cerezyme, but supplies of its Fabry disease drug Fabrazyme aren’t likely to be on track until a new production facility gains FDA approval later this year.